Navigation Links
Orally Disintegrating Tablets and Thin Films Poised to See Strong Growth
Date:4/18/2013

FALLS CHURCH, Va., April 18, 2013 /PRNewswire/ -- Orally disintegrating tablets (ODTs) are coming into their own as mainstream pharmaceutical products.  Oral thin films (OTFs) have also come into strong prominence with the launch of Suboxone® (buprenorphine and naloxone) thin films demonstrating a huge potential for thin films in prescription products.  Statistics have shown that four out of five patients prefer orally disintegrating dosage forms over conventional solid oral dosages.  These factors, coupled with convenience and compliance advantages, have been (and will continue to) pave the way for ODT and OTF drug product growth.

During a recent interview with Technology Catalysts, Bob Duffy , Marketing Manager, Excipients & Drug Delivery Systems for SPI Pharma, a leading developer of ODT formulations using its Pharmaburst® technology, stated, "Due to advances in various drug delivery technologies, of which SPI's Pharmaburst direct-compression platform is a market leader, ODTs are no longer only for treating niche therapeutic areas.  With improvements in mouthfeel, disintegration time, and the ability to handle higher drug loading, the ODT market is on the verge of becoming mainstream in a variety of both prescription and OTC medications for treating pain, cough/cold, sleep disorders, GERD, and ED."

The OTF market has received a huge boost with the phenomenal success of Reckitt Benckiser's prescription thin film, Suboxone.  Suboxone scored sales of $513 million in 2011 and accounted for 96 percent of the OTF market.  The success of this product demonstrates an increasing consumer acceptance of thin films as well the ability of pharmaceutical companies to successfully use thin films for lifecycle management. 

The ODT and OTF markets are discussed in depth in Technology Catalysts International's latest report, Orally Disintegrating Tablet and Film Technologies – Seventh Edition.  Key information presented in the report includes the growing Japanese generic market, ODTs in the emerging markets, ODT and OTF pipeline analysis, innovative developments for delivery of proteins and peptides via ODTs and OTFs, and new nutraceutical thin film technologies and products.

The report also includes a market analysis of both ODTs and OTFs, sales of leading ODT products in 2010-2011, ODT brand erosion by generics, late stage prescription OTFs, and the sales potential for OTFs with key APIs.  Most importantly, the report contains screened and confirmed business and technology licensing opportunities from around the globe.

For complete report prospectus, pricing, and ordering information, please refer to:

http://www.technology-catalysts.com/reports_services/odt7.asp

About Technology Catalysts International:

Technology Catalysts International ("TCI") was founded in 1979 and provides consulting services in technology transfer and business research. The company specializes in technology licensing, technology assessment, and business intelligence. With a focus on pharmaceuticals, drug delivery, consumer healthcare, and advanced materials/processes, TCI's core consulting services are based on continuous monitoring of technological product development activities on a global basis.  TCI is headquartered in the US and has offices in the UK, Germany, Czech Republic, China, Korea, Japan, India, and Latin America.

Contact:

Ajay Rastogi , Vice President
Technology Catalysts International
Telephone (703) 531-0257
arastogi@technology-catalysts.com
http://www.technology-catalysts.com


'/>"/>
SOURCE Technology Catalysts International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Researchers Developing New Multiple Sclerosis Drug That Can Be Taken Orally
2. Mylan Launches Generic Version of Zyprexa® Tablets
3. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
4. Mylan Launches Generic Version of Plavix® Tablets
5. Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
6. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
7. Mylan Launches Generic Version of Viramune® Tablets
8. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
9. Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with type 2 diabetes in Europe
10. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
11. Qualitest Receives FDA Approval for Levetiracetam Extended-Release Tablets, 500mg and 750mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
(Date:3/24/2017)... , March 24, 2017 ShangPharma, ... high-quality and cost-effective drug development and discovery ... and biotechnology industry, announced today the intent ... ShangPharma will be consolidating the Contract Research ... under Shanghai ChemPartner. These entities include ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... Texas (PRWEB) , ... March 23, 2017 , ... The ... 3rd location in the greater Houston Area. The new location is located at 2255 ... Luke’s Hospital in Springwoods Village. This newest location will provide patients living in the ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Center at 10 North Broadway Avenue, will be an educational and exciting program ... instruction in the management of chronic pain. , Oklahoma is in a healthcare ...
Breaking Medicine News(10 mins):